Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
0.131
-0.003 (-2.24%)
Apr 29, 2026, 12:32 PM EDT - Market open
Virax Biolabs Group Revenue
Virax Biolabs Group had revenue of $1.61K in the half year ending September 30, 2025, a decrease of -97.90%. This brings the company's revenue in the last twelve months to $2.99K, down -96.48% year-over-year. In the fiscal year ending March 31, 2025, Virax Biolabs Group had annual revenue of $6.33K, down -95.95%.
Revenue (ttm)
$2.99K
Revenue Growth
-96.48%
P/S Ratio
892.75
Revenue / Employee
$157
Employees
19
Market Cap
2.61M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionVRAX News
- 15 days ago - Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders - PRNewsWire
- 4 weeks ago - What's Behind The Jump In Virax Biolabs Stock? - Benzinga
- 4 weeks ago - Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation - PRNewsWire
- 5 months ago - Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement - PRNewsWire
- 5 months ago - Virax Biolabs Group Limited Announces $5 Million Private Placement - PRNewsWire
- 5 months ago - Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders - PRNewsWire
- 6 months ago - Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes - PRNewsWire
- 8 months ago - Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September - PRNewsWire